Combined treatment of giant cell bone tumor
https://doi.org/10.17650/2782-3687-2021-13-4-23-28
Abstract
Introduction. Giant cell tumor refers to tumors with an uncertain malignancy potential, has a locally aggressive course. Intra-focal resections performed for a giant cell tumor of long tubular bones are accompanied by the development of relapse in 30–46 % of cases. The combination of pathogenetic therapy with surgical intervention makes it possible to reduce the frequency of relapses in operable tumors after marginal and intra-focal resections, and in inoperable tumors to provide local control and relieve pain.
Objective – to analyze the results of combined treatment of patients with giant cell bone tumor.
Materials and methods. In the conditions of Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan, 13 patients aged 20 to 63 years are in the process of combined treatment of a giant cell tumor. As of November 2021, 7 patients have completed treatment.
Results. Among the 7 patients who completed treatment, 6 people were operated on (1 patient refused surgery). In 5 patients, intra-focal resection of the tumor with osteoinductive material “BoneMedic-S” was performed, in 1 patient with a giant cell tumor of the sciatic bone, resection of the sciatic bone was performed without reconstruction. 1 patient with a widespread tumor (sacral lesion) receives supportive treatment.
Conclusion. The combined approach in the treatment of giant-cell bone tumor allows performing a functional-saving, organpreserving surgical intervention, significantly reducing the risk of tumor recurrence and its malignant transformation.
About the Authors
I. R. Safin
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Tatarstan; Kazan State Medical Academy – branch of the Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Ildar Rafailovich Safin
29 Siberian Tract, Kazan 420029
11 Mushtari St., Kazan 420012
A. Yu. Rodionova
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Tatarstan
Russian Federation
Russian Federation
29 Siberian Tract, Kazan 420029
D. V. Rukavishnikov
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Tatarstan
Russian Federation
Russian Federation
29 Siberian Tract, Kazan 420029
R. Sh. Khasanov
Kazan State Medical Academy – branch of the Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
11 Mushtari St., Kazan 420012
R. N. Safin
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Tatarstan
Russian Federation
Russian Federation
29 Siberian Tract, Kazan 420029
References
1. Vinogradova T.P. Bone tumors. Moscow: Medicine, 1973. 336 p. (In Russ.)
2. Bludov A.B., Nered A.S., Zamogilnaya Ya.A., Kochergina N.V. Giant cell tumor of the bone. Sarkomy kostej, myagkikh tkanej i opukholi kozhi = Bone and soft tissue sarcomas, tumors of the skin 2014;1:16–34. (In Russ.)
3. McGrath P.J. Giant-cell tumour of bone: an analysis of fifty-two cases. J Bone Joint Surg Br 1972;54(2):216–29.
4. Zatsepin S.T. Bone pathology of adults: a guide for doctors. Moscow: Medicine, 2001. 640 p. (In Russ.)
5. Aliev M.D., Sushentsov Е.А. Oncoorthopedics today. Sarkomy kostej, myagkikh tkanej i opukholi kozhi = Bone and soft tissue sarcomas, tumors of the skin 2012;4:3–10. (In Russ.)
6. Mahson A.N., Schupak M.U., Bondarev A.V. Denosumab. Experience of conservative treatment giant cell bone tumor. Sarkomy kostej, myagkikh tkanej i opukholi kozhi = Bone and soft tissue sarcomas, tumors of the skin 2014;2:31–8. (In Russ.)
7. Gao Z., Yin J.-Q., X.-B. et al. Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement BMC Musculoskeletal Disorders 2014;15(1):330. Xie DOI: 10.1186/1471-2474-15-330.
8. Malawer M.M., Bickels J., I. et al. Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res 1999;359:176–88. Meller DOI: 10.1097/00003086-199902000-00019.
9. Boyle W.J., Simonet W.S., D.L. et al. Osteoclast differentiation and activation. Nature 2003;423(6937):337–42. Lacey DOI: 10.1038/nature01658.
10. Clines G.A., Mohammad K.S., Bao Y. et al. Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation. Mol Endocrinol 2007;21(2):486–98. DOI: 10.1210/me.2006-0346.
11. Hofbauer L.C., Schoppet M. Create a file for external citation management software. JAMA 2004;292(4):490–5. DOI: 10.1001/jama.292.4.490.
12. Atkins G.J., Haynes D.R., Graves S.E. et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors J Bone Miner Res 2000;15(4):640–9. DOI: 10.1359/jbmr.2000.15.4.640.
13. Rutkowski P., Gaston L., Borkowska A. et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – multicenter analysis outside clinical trial. Eur J Surg Oncol 2018;44(9):1384–90. DOI: 10.1016/j.ejso.2018.03.020.
14. Roodman D. Mechanisms of bone metastasis. N Engj J Med 2004;350:1655–64. DOI: 10.1056/NEJMra030831.
Review
For citations:
Safin I.R., Rodionova A.Yu., Rukavishnikov D.V., Khasanov R.Sh., Safin R.N. Combined treatment of giant cell bone tumor. Bone and soft tissue sarcomas, tumors of the skin. 2021;13(4):23-28. (In Russ.) https://doi.org/10.17650/2782-3687-2021-13-4-23-28
Views:
246
Email this article 
